Magdalena Minnion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Magdalena Minnion has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Martin Feelisch
University of Southampton
3 shared publications A. Titia Lely
1 shared publication- Alice P. Sowton
Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK
1 shared publication - Andreas Pasch
Institute for Physiology and Pathophysiology, Johannes Kepler University Linz , Linz
1 shared publication - Andrew J. Murray
Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK
1 shared publication Benjamin D. Thackray
University of Cambridge
1 shared publication
Latest Publications
- Open Access
Liposomal encapsulation of L-arginine and L-citrulline enhances therapeutic effects in a rat model of Preeclampsia and Fetal Growth Restriction
Background: L-arginine and L-citrulline improve vascular health in Preeclampsia (PE) and Fetal growth restriction (FGR). However, the short half-life of these amino acids limits their efficacy. This study investigates pharmacokinetics, delivery, and therapeutic outcomes of liposomal encapsulation of L-arginine and L-citrulline in a rat model of PE and FGR. Method: Firstly, the pharmacokinetics of liposome-encapsulated L-arginine (Encapsulated L-arg) was compared to that of free L-arginine (Free L-arg) in normal pregnant (NP) dams, following single intravenous administration. Secondly, the therapeutic effect on maternal blood pressure and fetal weight were studied in NP rats and the reduced uterine perfusion pressure (RUPP) model for PE and FGR. Treatment groups consisted of Encapsulated L-arginine and L-citrulline (Encapsulated AAs); ratio 1:1, Free L-arginine and L-citrulline (AAs), or PBS, administered intravenously for five consecutive days. Blood and organs were analyzed for amino acid concentrations and fluorescence to assess the biodistribution profile of the liposomes. Nitrite and nitrate were quantified to measure changes in endogenous nitric oxide production in the pharmacokinetic study. Results: Liposomal encapsulation increased the area under the curve of blood arginine concentration-time curves >120-fold. Encapsulated AAs led to a marked increase in plasma and placental tissue concentrations compared to their free forms. Encapsulated AAs reduced maternal blood pressure in RUPP without affecting fetal weight. Enlarged spleens were observed in both Encapsulated AAs groups. Conclusions: The enhanced pharmacokinetics enabled by liposomal encapsulation effectively increased placental delivery of L-arginine and L-citrulline and reduced hypertension. Optimizing composition could enhance efficacy on FGR, making Encapsulated AAs a promising strategy for managing PE and FGR. The etiology of the observed maternal splenomegaly observed warrants further research before this novel approach can be clinically implemented.
Open AccessLiposomal encapsulation of L-arginine and L-citrulline enhances therapeutic effects in a rat model of Preeclampsia and Fetal Growth Restriction
Background: L-arginine and L-citrulline improve vascular health in Preeclampsia (PE) and Fetal growth restriction (FGR). However, the short half-life of these amino acids limits their efficacy. This study investigates pharmacokinetics, delivery, and therapeutic outcomes of liposomal encapsulation of L-arginine and L-citrulline in a rat model of PE and FGR. Method: Firstly, the pharmacokinetics of liposome-encapsulated L-arginine (Encapsulated L-arg) was compared to that of free L-arginine (Free L-arg) in normal pregnant (NP) dams, following single intravenous administration. Secondly, the therapeutic effect on maternal blood pressure and fetal weight were studied in NP rats and the reduced uterine perfusion pressure (RUPP) model for PE and FGR. Treatment groups consisted of Encapsulated L-arginine and L-citrulline (Encapsulated AAs); ratio 1:1, Free L-arginine and L-citrulline (AAs), or PBS, administered intravenously for five consecutive days. Blood and organs were analyzed for amino acid concentrations and fluorescence to assess the biodistribution profile of the liposomes. Nitrite and nitrate were quantified to measure changes in endogenous nitric oxide production in the pharmacokinetic study. Results: Liposomal encapsulation increased the area under the curve of blood arginine concentration-time curves >120-fold. Encapsulated AAs led to a marked increase in plasma and placental tissue concentrations compared to their free forms. Encapsulated AAs reduced maternal blood pressure in RUPP without affecting fetal weight. Enlarged spleens were observed in both Encapsulated AAs groups. Conclusions: The enhanced pharmacokinetics enabled by liposomal encapsulation effectively increased placental delivery of L-arginine and L-citrulline and reduced hypertension. Optimizing composition could enhance efficacy on FGR, making Encapsulated AAs a promising strategy for managing PE and FGR. The etiology of the observed maternal splenomegaly observed warrants further research before this novel approach can be clinically implemented.
- Open Access
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328 (1) , E69-E91
Chronic inorganic nitrate supplementation does not improve metabolic health and worsens disease progression in mice with diet-induced obesity
Inorganic nitrate has been suggested to be of therapeutic benefit in obesity-related conditions, as it increases nitric oxide bioavailability, enhances mitochondrial β-oxidation, and reverses metabolic syndrome in eNOS−/− mice. However, we here show that over 12 months nitrate was ineffective in preventing metabolic consequences in high fat, high sucrose-fed mice and worsened aspects of metabolic health, impairing cholesterol handling, increasing cardiac fibrosis, and exacerbating steatotic liver disease progression, with acceleration to hepatocellular carcinoma.
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328 (1) , E69-E91
Open AccessChronic inorganic nitrate supplementation does not improve metabolic health and worsens disease progression in mice with diet-induced obesity
Inorganic nitrate has been suggested to be of therapeutic benefit in obesity-related conditions, as it increases nitric oxide bioavailability, enhances mitochondrial β-oxidation, and reverses metabolic syndrome in eNOS−/− mice. However, we here show that over 12 months nitrate was ineffective in preventing metabolic consequences in high fat, high sucrose-fed mice and worsened aspects of metabolic health, impairing cholesterol handling, increasing cardiac fibrosis, and exacerbating steatotic liver disease progression, with acceleration to hepatocellular carcinoma.
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (8) , 1884-1894
Serum Calcification Propensity Is Increased in Myocardial Infarction and Hints at a Pathophysiological Role Independent of Classical Cardiovascular Risk Factors
BACKGROUND: Vascular calcification is associated with increased mortality in patients with cardiovascular disease. Secondary calciprotein particles are believed to play a causal role in the pathophysiology of vascular calcification. The maturation time (T 50 ) of calciprotein particles provides a measure of serum calcification propensity. We compared T 50 between patients with ST-segment–elevated myocardial infarction and control subjects and studied the association of T 50 with cardiovascular risk factors and outcome. METHODS: T 50 was measured by nephelometry in 347 patients from the GIPS-III trial (Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction: a Randomized Controlled Trial) and in 254 matched general population controls from PREVEND (Prevention of Renal and Vascular End-Stage Disease). We also assessed the association between T 50 and left ventricular ejection fraction, as well as infarct size, the incidence of ischemia-driven reintervention during 5 years of follow-up, and serum nitrite as a marker of endothelial dysfunction. RESULTS: Patients with ST-segment–elevated myocardial infarction had a significantly lower T 50 (ie, higher serum calcification propensity) compared with controls (T 50 : 289±63 versus 338±56 minutes; P 50 was associated with female sex, lower systolic blood pressure, lower total cholesterol, lower LDL (low-density lipoprotein) cholesterol, lower triglycerides, and higher HDL (high-density lipoprotein) cholesterol but not with circulating nitrite or nitrate. Ischemia-driven reintervention was associated with higher LDL ( P =0.03) and had a significant interaction term for T 50 and sex ( P =0.005), indicating a correlation between ischemia-driven reintervention and T 50 above the median in men and below the median in women, between 150 days and 5 years of follow-up. CONCLUSIONS: Serum calcification propensity is increased in patients with ST-segment–elevated myocardial infarction compared with the general population, and its contribution is more pronounced in women than in men. Its lack of/inverse association with nitrite and blood pressure confirms T 50 to be orthogonal to traditional cardiovascular disease risk factors. Lower T 50 was associated with a more favorable serum lipid profile, suggesting the involvement of divergent pathways of calcification stress and lipid stress in the pathophysiology of myocardial infarction.
- 1 August 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (8) , 1884-1894
Open AccessSerum Calcification Propensity Is Increased in Myocardial Infarction and Hints at a Pathophysiological Role Independent of Classical Cardiovascular Risk Factors
BACKGROUND: Vascular calcification is associated with increased mortality in patients with cardiovascular disease. Secondary calciprotein particles are believed to play a causal role in the pathophysiology of vascular calcification. The maturation time (T 50 ) of calciprotein particles provides a measure of serum calcification propensity. We compared T 50 between patients with ST-segment–elevated myocardial infarction and control subjects and studied the association of T 50 with cardiovascular risk factors and outcome. METHODS: T 50 was measured by nephelometry in 347 patients from the GIPS-III trial (Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction: a Randomized Controlled Trial) and in 254 matched general population controls from PREVEND (Prevention of Renal and Vascular End-Stage Disease). We also assessed the association between T 50 and left ventricular ejection fraction, as well as infarct size, the incidence of ischemia-driven reintervention during 5 years of follow-up, and serum nitrite as a marker of endothelial dysfunction. RESULTS: Patients with ST-segment–elevated myocardial infarction had a significantly lower T 50 (ie, higher serum calcification propensity) compared with controls (T 50 : 289±63 versus 338±56 minutes; P 50 was associated with female sex, lower systolic blood pressure, lower total cholesterol, lower LDL (low-density lipoprotein) cholesterol, lower triglycerides, and higher HDL (high-density lipoprotein) cholesterol but not with circulating nitrite or nitrate. Ischemia-driven reintervention was associated with higher LDL ( P =0.03) and had a significant interaction term for T 50 and sex ( P =0.005), indicating a correlation between ischemia-driven reintervention and T 50 above the median in men and below the median in women, between 150 days and 5 years of follow-up. CONCLUSIONS: Serum calcification propensity is increased in patients with ST-segment–elevated myocardial infarction compared with the general population, and its contribution is more pronounced in women than in men. Its lack of/inverse association with nitrite and blood pressure confirms T 50 to be orthogonal to traditional cardiovascular disease risk factors. Lower T 50 was associated with a more favorable serum lipid profile, suggesting the involvement of divergent pathways of calcification stress and lipid stress in the pathophysiology of myocardial infarction.